Navigation Links
NIST standard available for better diagnosis, treatment of cytomegalovirus
Date:1/11/2012

A new clinical Standard Reference Material (SRM) from the National Institute of Standards and Technology (NIST) will help health care professionals more accurately diagnose and treat cytomegalovirus (CMV), a common pathogen that is particularly dangerous for infants and persons with weakened immune systems.

CMV is found in 50 to 80 percent of the population. It is a member of the herpes family of viruses that includes two herpes simplex viruses (the causes of cold sores and genital herpes), the varicella-zoster virus (the cause of chicken pox and shingles) and the Epstein-Barr virus (the cause of mononucleosis). Like its cousin herpes viruses, CMV generally remains latent in an infected person unless certain conditions trigger its activation. CMV poses a significant health risk to people who are immunocompromised (such as organ transplant patients or cancer patients undergoing chemotherapy) and babies who receive the virus from their mothers before birth. Congenital CMV infections cause more long-term problems and childhood deaths than many other prenatal disorders including fetal alcohol syndrome, Down syndrome and neural tube defects such as spinal bifida.

If a CMV infection becomes dangerous, antiviral agents can be used to moderate the impact. Unfortunately, many of these compounds are toxic, so a physician must know the severity of the infectiona measure known as viral load (number of virus copies per microliter of blood)to prescribe the optimal dosage and duration of treatment. The current means of measuring viral load is to use polymerase chain reaction (PCR)the standard technique for "amplifying" or making multiple copies of a DNA segment or moleculeto amplify a region of the CMV gene and then use a calibration curve to estimate the number of virus particles in the original sample. Accuracy of these measurements can vary greatly from one test facility to another as there are many different PCR protocols used to determine viral load, including commercial and "in-house" (privately developed) laboratory assays.

The new NIST reference, SRM 2366, addresses the variability problem by providing a standardized CMV DNA. Consistency of the viral DNA in the standard was ensured by manufacturing it in Escherichia coli bacteria. These E. coli cells each contain a copy of the CMV genome in a "DNA construct"an artificially constructed segment of nucleic acid that codes for a specific product, in this case, CMV DNA. The DNA copies made by this E. coli cell culture "factory" can then be purified and quantified using digital PCR

SRM 2366 consists of three solutions, each with a specific concentration of CMV DNA copies per microliter: 420, 1,702 and 19,641. These are designed to qualify prepared calibration samples (known as calibrants). They also can be used as quality control samples for diagnostic equipment. For added traceability, the SRM certificate of analysis includes the genetic sequences of the nine CMV genome regions copied for the standard.

SRM 2366 joins more than 50 reference materials produced by NIST for quality control in clinical testing. Standard Reference Materials are among the most widely distributed and used products from NIST. The agency prepares, analyzes and distributes about 1,300 different materials that are used throughout the world to check the accuracy of instruments, validate test procedures and serve as the basis for quality control standards worldwide.


'/>"/>

Contact: Michael E. Newman
michael.newman@nist.gov
301-975-3025
National Institute of Standards and Technology (NIST)
Source:Eurekalert  

Related biology news :

1. When standard treatment fails: Jefferson to start unique immunotherapy for brain tumor patients
2. ATS statement regarding White House decision to delay new ozone standard
3. Its your standard pilot project: NIST to offer documentary standards to first responders
4. Inverting a standard experiment sometimes produces different results
5. NIST prototypes framework for evaluating sustainability standards
6. Study examines folic acid absorption rates from softgel capsule and standard tablet
7. ESHRE sets standards for cross-border reproductive care
8. IOF-ISCD collaboration to create courses setting highest standards in diagnostic training
9. Advertising Research Foundation Develops Standards for Neuromarketing Research
10. Quality standards for biological, chemical drugs and public health are focus of India meeting
11. Standardized protocols would greatly enhance clinical and research potential of BTMs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NIST standard available for better diagnosis, treatment of cytomegalovirus
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology: